Techsomed News
11 articles
/PRNewswire/ -- Techsomed Ltd., a pioneering medical AI-powered software company specializing in image-guided therapy is pleased to announce a collaboration...
Techsomed Ltd., a medical AI-powered software company, has announced a pilot collaboration with Medtronic, a leader in healthcare technology. This partnership integrates Techsomeds BioTraceIO360™ software with Medtronics Emprint™ microwave ablation system to enhance image-guided ablation therapy. The collaboration aims to improve treatment precision by providing interventional radiologists with advanced capabilities for real-time visualization and predictive margin control. Techsomeds platform leverages generative AI to unify CT, MRI, and ultrasound data, enabling physicians to plan and validate treatments with greater accuracy. This partnership is expected to set a new standard in minimally invasive ablation treatment.
Partners
/PRNewswire/ -- Techsomed, a leader in AI-Driven Precision for Image-Guided Care, today announces U.S. FDA 510 (k) clearance expanding indications for...
Techsomed, a leader in AI-driven precision for image-guided care, has received U.S. FDA 510(k) clearance for its BioTraceIO360 software platform, expanding its indications to include percutaneous ablation of soft tissue in the kidney. This clearance builds on its previous liver application approval, advancing Techsomeds vision for a multi-organ, hardware-agnostic image-guided therapy platform. The BioTraceIO360 platform offers planning, simulation, guidance, and verification for minimally invasive procedures, enhancing precision and consistency in interventional oncology. The software is now available in the U.S. for both liver and kidney ablation workflows, marking a significant milestone for the company.
FDA approved/pending approval
/PRNewswire/ -- Techsomed Ltd., a pioneering global medical software company, today announced the appointment of Robert (Bob) Gerberich as Chief Commercial...
Techsomed Ltd., a global medical software company, has appointed Robert (Bob) Gerberich as Chief Commercial Officer and Head of North America. Gerberich, with over 30 years of experience in the Medical Device, MedTech, and Diagnostics sectors, will lead global commercial functions and North America operations. Techsomed specializes in the AI-powered BioTraceIO™ software suite for Image-Guided Ablation Therapy, which includes FDA-cleared BioTraceIO™ Vision and BioTraceIO™ Precision. The appointment aims to accelerate the U.S. launch and global expansion of these innovative technologies, enhancing patient care and reducing costs in the healthcare market.
Management Changes
Techsomed's BioTrace Solution Achieves De Novo Clearance from FDA as the First Ultrasound-Based Software for Tissue Response Prediction in Liver Tumor Ablation
Techsomed Announces FDA Clearance for Ablation Treatment Planning and Confirmation Software
Techsomed Announces Field Evaluation of its image guided ablation therapy software using GE HealthCare LOGIQ™ ultrasound systems at top US clinical sites
TechsoMed Ltd. announces the opening of a new German Subsidiary, as a strategic collaboration with Research Institute Fraunhofer MEVIS, to accelerate End-to-End Solution for Image-Guided Tumor Ablation Therapy
TechsoMed Completes Enrollment in United States Pivotal Trial of BioTraceIO Software for Liver Ablation Outcomes Assessment - Endovascular Today
The Japanese subsidiary of TechsoMed Ltd., an Israeli company that develops ultrasound based image analysis software system for tissue damage monitoring and control in multi-clinical applications, steadily expands its business | 2022 - Events & News - Investing in Japan - Japan External Trade Organization
TechsoMed Raises $7 Million Series B financing led by Axil Capital
TechsoMed, a developer of AI and Algorithm powered real-time tissue damage imaging technology, has closed a US$7 million Series B equity financing round. The funding round was led by Axil Capital and included participation from Yongjin Capital, Cobro Ventures, Magna Capital Partners, and Radianx Capital, as well as existing investors Johnson & Johnson Innovation – JJDC, Inc. and NextLeap Ventures. The companys technology, called BioTrace, has the potential to help physicians ensure treatment accuracy and increase treatment efficacy. By tracing the tissues biological response, BioTrace provides a unique damage map that represents the full extent of damage as seen 24 hours post-treatment. TechsoMed is collaborating with medical centers worldwide to secure regulatory approval for its BioTrace system in liver tumor ablation and is also developing the system for cardiac and pain ablation procedures.
Investment
Thermal ablation treatment co Techsomed raises $2.6m
Israeli thermal ablation treatment company Techsomed has raised $2.6 million in a financing round led by Johnson & Johnson Innovation. The funds will be used for further development of its BioTrace image analysis system for predicting post-treatment ablation morphology in real time. The system aims to enhance the surgeons level of control and accuracy during thermal ablation procedures, minimizing healthy tissue damage and maximizing target tissue ablation. The financing round demonstrates confidence in Techsomeds technology and its potential to make thermal ablation safer and more effective.
Investment
